More Big-name Pharma Firms Join NCATS Therapeutic Repurposing Effort | GenomeWeb

NEW YORK (GenomeWeb News) – The National Center for Advancing Translational Sciences said today that five additional pharmaceutical companies have joined its new program to enable researchers to study new uses for chemical compounds that have been set aside by drug makers

The five new participants in the NCATS program are Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical Research and Development, and Sanofi.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.